课题基金 / 基金详情

Phenocopying ATM loss via modulation of cellular metabolism to overcome resistance to the ATR inhibitor

Phenocopying ATM loss via modulation of cellular metabolism to overcome resistance to the ATR inhibitor
通过调节细胞代谢来复制 ATM 损失,以克服对 ATR 抑制剂的耐药性
批准号:
2548307
负责人:
金额:
$0.0万
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2021
资助国家:
英国
项目状态:
未结题
起止时间:
2021 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Our objectives are (i) to characterise the role of ATM in generating resistance toATR inhibitors by investigating the effect of ATM deficiency on cellular metabolism; (ii) to investigatewhether we can recreate the metabolic profile of ATM-deficient cells via targeting cellular metabolism and ifthis would sensitize cancer cells to AZ6738, mimicking ATM loss. Understand how ATM contributes togenerate resistance to AZ6738, a drug currently in clinical trials, our proposal is of clear relevance for thepharmaceutical industry and thus in the remit of BBSRC.Aim1: Using tracer compounds and unpublished preliminary data form AZ, we will investigate themechanisms responsible for the metabolic profile of ATM deficient cells.Aim2: inhibitors are already available for the majority of metabolic pathways, thus we will take advantage ofthis underexploited toolbox to mirror the ATM-deficient metabolic phenotype identified in Aim1 and test ifthis will sensitise ATM proficient cells to AZ6738.Aim3: in the cerebellar cortex of Ataxia-telangiectasia patients (carrying mutations in the ATM gene) a set ofmitochondrial genes is deregulated5. In collaboration with GS (UCL - second supervisor) we will identifycells with a similar mitochondrial phenotype using publicly available dataset (i.e. CCLE) and will test thesensitivity to AZ6738 of cells with different mitochondria phenotypes.Expected outcome: understand how changes in cellular metabolism may lead to drug resistance
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
TSAb通过mTOR信号诱导线粒体缺陷性自噬在ATM中的作用及机制研究
  • 批准号:
    2026JJ81820
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    张韵
  • 依托单位:
基于“去宛陈莝,精生形盛”探讨白芍七物颗粒通过CDK4/6-CCND1/2/3-ATM通路时序调控UC肠黏膜细胞周期与DNA损伤修复的机制研究
基于晶体结构和类药性质指导选择性ATM 小分子抑制剂的设计、合成及抗胶质母细胞瘤的活性机制研究
  • 批准号:
    JCZRQN202500438
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
新型铜载体天然产物Chalkphomycin通过ATM酶-CHK2-Cyclin D1轴抗黑色素瘤作用机制研究
  • 批准号:
    2025JJ80302
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    龚邦
  • 依托单位: